Web Results

en.wikipedia.org/wiki/MedImmune,_Inc._v._Genentech,_Inc.

MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007) was a decision by the Supreme Court of the United States involving patent law. It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech. One of the central issues was whether a licensee retained the right to  ...

law.justia.com/cases/federal/appellate-courts/ca3/15-3805/15-3805-2017-05-01.html

May 1, 2017 ... Qui tam relator failed to satisfy the False Claims Act's materiality requirement in alleging that the manufacturer of a widely-prescribed cancer drug, Avastin, suppressed data that caused doctors to certify incorrectly that Avastin was “ reasonable and necessary” for certain at-risk Medicare patients. Avastin is ...

www.concertpharma.com/wp-content/uploads/2017/10/2017-10-16-08-Patent-Owner-Preliminary-Response.pdf

Oct 16, 2017 ... Altana Pharma AG v. Teva Pharmaceuticals USA, Inc., ..... B. Belleau et al, Effect of Deuterium Substitution in Sympathomimetic. Amines on Adrenergic Responses, 133 SCIENCE ..... See, e.g., Hospira, Inc. v. Genentech, Inc., IPR2017-00739, Paper 16 at 14, 16-17 (a petitioner's enablement challenge to a  ...

www2.ca3.uscourts.gov/opinarch/153805p.pdf

May 1, 2017 ... Genentech, filed a qui tam action soon after leaving the company. ... Petratos claimed Genentech's data suppression was part of a ... Court's order granting appellees' motion to dismiss for failure to state a claim.” United States ex rel. Wilkins v. United. Health Grp., Inc., 659 F.3d 295, 302 (3d Cir. 2011). We.

casetext.com/case/medimmune-inc-v-genentech-inc-no-05-608-us-192007

“Holding "that petitioner was not required, insofar as Article III is concerned, to break or terminate its 1997 license agreement before seeking a declaratory judgment in federal court that the underlying patent is invalid, unenforceable, or not infringed"”Musselman v. Blue Cross & Blue Shield Alabama, No. 13-14250 ( 11th Cir.

www.law.cornell.edu/supremecourt/text/05-608

After the parties entered into a patent license agreement covering, inter alia, respondents' then-pending patent application, the application matured into the “ Cabilly II” patent. Respondent Genentech, Inc., sent petitioner a letter stating that Synagis, a drug petitioner manufactured, was covered by the Cabilly II patent and that ...

scocal.stanford.edu/opinion/city-hope-v-genentech-33188

CITY OF HOPE NATIONAL MEDICAL ) CENTER, ). Plaintiff and Respondent, S129463 v. Ct.App. 2/2 B161549 GENENTECH, INC., Los Angeles County Defendant and ...... Xilinx, Inc./Legal 2100 Logic Drive San Jose, CA. 30, Microsoft Corporation (Amicus curiae) Represented by Gregory P. Stone Munger, Tolles Et Al

www.fcaupdate.com/2017/05/third-circuit-affirms-dismissal-of-fca-suit-against-genentech-based-on-supreme-courts-materiality-standard

May 10, 2017 ... On May 1, 2017, the US Court of Appeals for the Third Circuit affirmed the dismissal of United States ex rel. Petratos, et al. v. Genentech, Inc., et al.,

www.fcaupdate.com/tag/united-states-ex-rel-petratos-et-al-v-genentech

May 10, 2017 ... On May 1, 2017, the US Court of Appeals for the Third Circuit affirmed the dismissal of United States ex rel. Petratos, et al. v. Genentech, Inc., et al., No. 15- 3801 (3d. Cir. May 1, 2017). On appeal from the US District Court for the District of New Jersey, the Third Circuit reinforced the applicability … Continue ...